- Home
- ACIC vs LAB Comparison
ACIC vs LAB Comparison
Compare ACIC & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- LAB
- Stock Information
- Founded
- ACIC 1999
- LAB 1999
- Country
- ACIC United States
- LAB United States
- Employees
- ACIC N/A
- LAB N/A
- Industry
- ACIC Property-Casualty Insurers
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- ACIC Finance
- LAB Industrials
- Exchange
- ACIC Nasdaq
- LAB Nasdaq
- Market Cap
- ACIC 569.8M
- LAB 562.1M
- IPO Year
- ACIC N/A
- LAB 2011
- Fundamental
- Price
- ACIC $12.51
- LAB $1.30
- Analyst Decision
- ACIC Buy
- LAB Strong Buy
- Analyst Count
- ACIC 1
- LAB 2
- Target Price
- ACIC $16.00
- LAB $2.88
- AVG Volume (30 Days)
- ACIC 120.2K
- LAB 1.8M
- Earning Date
- ACIC 02-27-2025
- LAB 02-26-2025
- Dividend Yield
- ACIC 3.99%
- LAB N/A
- EPS Growth
- ACIC N/A
- LAB N/A
- EPS
- ACIC 1.76
- LAB N/A
- Revenue
- ACIC $290,784,000.00
- LAB $155,902,000.00
- Revenue This Year
- ACIC N/A
- LAB $62.60
- Revenue Next Year
- ACIC $12.68
- LAB $9.19
- P/E Ratio
- ACIC $7.11
- LAB N/A
- Revenue Growth
- ACIC 1.02
- LAB 48.23
- 52 Week Low
- ACIC $8.82
- LAB $1.17
- 52 Week High
- ACIC $15.08
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- ACIC 51.61
- LAB 35.51
- Support Level
- ACIC $11.66
- LAB $1.17
- Resistance Level
- ACIC $13.50
- LAB $1.51
- Average True Range (ATR)
- ACIC 0.44
- LAB 0.10
- MACD
- ACIC 0.11
- LAB 0.00
- Stochastic Oscillator
- ACIC 46.20
- LAB 32.50
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.